Axsome Therapeutics has again demonstrated the strength of its intellectual property portfolio, shaking hands with Teva on a settlement in patent-litigation proceedings that will keep the Israeli firm’s proposed generic version of Axsome’s Auvelity (dextromethorphan/bupropion) treatment for major depressive disorder off the market until at least September 2038.
Last year, the New York-based originator brokered a deal with Unichem forcing the Indian firm to wait until June 2042 at the earliest to launch its...